Results 251 to 260 of about 21,005 (271)

Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of SF3B1 mutations

bioRxiv
Background Mutations in splicing factor 3B subunit 1 (SF3B1) frequently occur in patients with chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). These mutations have a different effect on the disease prognosis with beneficial effect
Alicja Pacholewska, M. Lienhard, M. Brüggemann, Heike Hänel, Lorina Bilalli, Anja Königs, Kerstin Becker, K. Köhrer, Jesko Kaiser, Holger Gohlke, N. Gattermann, Michael Hallek, C. Herling, Julian König, C. Grimm, Ralf Herwig, K. Zarnack, Michal R. Schweiger   +17 more
semanticscholar   +1 more source

Abstract 4615: Influence of SF3B1 gene mutation is different from that of Sf3B1 inhibitor in colorectal cancer

Cancer Research, 2014
Abstract Purpose: We have reported that SF3B1 gene mutations are rare in colorectal cancer patients and SF3B1 gene mutations in codon 1074 are responsible for resistance to SF3B1 inhibitor (FR901464, FR) at the AACR annual meeting 2013. SF3B1 gene mutations in hematological malignancies are considered to be related to tumor progression ...
Tomoki Yamano, Shuji Kubo, Nagahide Matsubara, Aya Yano, Naohiro Tomita   +4 more
openaire   +1 more source

Abstract 4350: Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer.

Cancer Research, 2013
Abstract Purpose: FR901464 (FR) is an antitumor agent that specifically binds to and inhibits the function of splicing factor 3B subunit 1 (SF3B1). Higher frequencies of SF3B1 gene mutations and their relevance to cancer progression have been shown in studies of hematological malignancies.
Tomoki Yamano, Hidenori Nakajima, Satoshi Tsuda, Shuji Kubo, Mie Hamanaka, Masayoshi Kobayashi, Daisuke Yamagishi, Takashi Kuno, Kiyoshi Tsukamoto, Astuko Tamamoto, Masafumi Noda, Nagahide Matsubara, Dave SB Hoon, Naohiro Tomita   +13 more
openaire   +1 more source

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment

Blood
Background Both MDS-SF3B1 and isolated del(5q) MDS are recognized by WHO and ICC 2022 as unique molecularly-defined MDS entities. Reports including the molecular revised international prognostic scoring system (IPSS-M) indicate that concomitant ...
R. Komrokji, Zaker I. Schwabkey, N. Al Ali, Luis E. Aguirre, Maximilian F. Stahl, S. Ball, Emily Mason, M. Savona, V. Santini, A. Consagra, U. Platzbecker, A. Kubasch, Y. Madanat, P. Fenaux, Lin-Pierre Zhao, M. Sekeres, Namrata S. Chandhok, M. D. Della Porta, L. Lanino, A. Dezern, D. Sallman, Zhuoer Xie, E. Padron, K. Sasaki, Kensuke Takaoka, Akhil Jain, M. del Rey, M. Díez-Campelo, G. Garcia-Manero   +28 more
semanticscholar   +1 more source

Impact of SF3B1 mutation in myelofibrosis

Leukemia & Lymphoma, 2022
Jayastu Senapati, Srdan Verstovsek, Lucia Masarova, Naveen Pemmaraju, Keyur P. Patel, Guillermo Montalban-Bravo, Sherry A. Pierce, Lingsha Zhou, Guillermo Garcia-Manero, Hagop M. Kantarjian, Prithviraj Bose   +10 more
openaire   +2 more sources

101 SF3B1 Mutation and Overlapping Features of MDS/MPN-SF3B1-T and CLL: A Diagnostic Challenge

American Journal of Clinical Pathology
Abstract Introduction/Objective SF3B1 mutations are associated with several hematologic malignancies, including chronic lymphocytic leukemia (CLL) and myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T). CLL cases with SF3B1 mutations often show
Zehra Kocas, Ali Tug, Jonathan Freeman
openaire   +1 more source

MDS-Associated SF3B1 Mutations Promote Aberrant Hematopoietic Cell Fate Choice By Disrupting Mediator Kinase Module Component CDK8

Blood
Somatic SF3B1 mutations are believed to arise early in the pathogenesis of clonal myeloid disorders such as myelodysplastic syndromes (MDS). Studies show that SF3B1 mutations bias hematopoietic stem and progenitor cells (HSPCs) toward the myeloid ...
Elizabeth A. Bonner, Axia Song, Erica Arriaga-Gomez, Katherine Gadek, Laura Baquero Galvis, Jonathan Linton, Rasika Venkataraman, Sayantani Sinha, Anthony Rongvaux, Myron Evans, Sergei Doulatov, Stanley C. Lee   +11 more
semanticscholar   +1 more source

Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms

Human Pathology, 2019
The introduction of next-generation sequencing has broadened the genetic landscape of myeloproliferative neoplasms (MPNs) beyond JAK2, MPL, and CALR. However, the biological role and clinical impact of most other mutations are not well defined. We interrogated 101 genes in 143 BCR-ABL1-negative MPNs in chronic phase from 2 large institutions.
Leonardo, Boiocchi, Robert P, Hasserjian, Olga, Pozdnyakova, Waihay J, Wong, Jochen K, Lennerz, Long Phi, Le, Dora, Dias-Santagata, Anthony J, Iafrate, Gabriela S, Hobbs, Valentina, Nardi   +9 more
openaire   +2 more sources

A Murine Model Harboring Cooperating DNMT3A and SF3B1 Mutations Phenocopies SF3B1 Driven Myelodysplastic Syndrome

Blood, 2022
Lashanale Wallace, Ana Leal-Cervantes, Amina Metidji, Jacquelyn Myers, Chandra Rolle, Heather Tillman, Esther A. Obeng   +6 more
openaire   +1 more source

Mutant SF3B1 splices a more leukemogenic EVI1

Blood, 2022
openaire   +2 more sources